Sequencing therapy in metastatic renal cell cancer

Seminars in Oncology

Volumn 40, Issue 4, 2013, Pages 465-471

  Escudier, Bernard ^a   Gore, Martin ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN;

ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG TREATMENT FAILURE; DYSPHONIA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883197565     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.05.002     Document Type: Article

References (37)

1. M. Sun, R. Thuret, and F. Abdollah Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis Eur Urol 59 2011 135 141
2. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 3 2004 454 463
3. J. Manola, P. Royston, and P. Elson Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group Clin Cancer Res 17 2011 5443 5450
4. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 34 2009 5794 5799
5. B. Escudier, T. Eisen, and C. Porta ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 65 71
6. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
7. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 9807 2011 1931 1939
8. D.Y. Heng, W. Xie, and G.A. Bjarnason A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): results from a large international study J Clin Oncol 28 suppl 2010 15s abstr 4523
9. Al-Marrawi MY, Rini BI, Harshman LC, et al. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). Presented at ASCO Annual Meeting. 2011, Chicago/ESMO 2011, Stockholm.
10. Levy A, Menard J, Albiges-Sauvin L, et al. Treatment (trx) modalities after a front line targeted therapies in patients (pts) with metastatic renal cell carcinoma (mRCC). Presented at the ECCO ESMO Multidisciplinary Congress, 2011;7153. ASCO 2011, Chicago/ESMO 2011, Stockholm
11. Albiges L, Iacovelli R, Porta C, et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib: is there any active treatment? Presented at the ECCO ESMO Multidisciplinary Congress, 2011;7143. ASCO 2011, Chicago/ESMO 2011, Stockholm
12. D.Y. Heng, M.J. Mackenzie, and U.N. Vaishampayan Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy Ann Oncol 23 6 2012 1549 1555
13. B.I. Rini, P. Tomczak, and A. Kaprin Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial J Clin Oncol 29 suppl 7 2011 abstr 4503
14. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
15. B. Escudier, C. Szczylik, C. Porta, and M. Gore Treatment selection in metastatic renal cell carcinoma: expert consensus Nat Rev Clin Oncol 9 2012 327 337
16. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
17. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
18. R.J. Motzer, B.I. Rini, and R.M. Bukowski Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2006 2516 2524
19. B. Escudier, J. Roigas, and S. Gillessen Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
20. O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
21. D.A. Nosov, B. Esteves, and O.N. Lipatov Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma J Clin Oncol 30 14 2012 1678 1685
22. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
23. M.B. Atkins, M. Hidalgo, and W.M. Stadler Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
24. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
25. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 18 2010 4256 4265
26. B. Escudier, J. Bellmunt, and S. Negrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 13 2010 2144 2150
27. S. Bracarda, J. Bellmunt, and B. Melichar Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial BJU Int 107 2 2011 214 219
28. M.J. Mackenzie, B.I. Rini, and P. Elson Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann Oncol 22 2011 145 148
29. B.I. Rini, G. Wilding, and G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
30. I.N. Zama, T.E. Hutson, and P. Elson Sunitinib rechallenge in metastatic renal cell carcinoma patients Cancer 116 23 2010 5400 5406
31. Hutson TE, Escudier B, Esteban E, et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial. Proc European Society of Medical Oncology Congress, Vienna, Austria September 28-October 2, 2012; abstract LBA22.
32. M.M. Vickers, T.K. Choueiri, and M. Rogers Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy Urology 76 2 2010 430 434
33. J.A. Reeves, D.R. Spigel, D.B. Daniel, E.K. Friedman, H.A. Burris, and J.D. Hainsworth Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: a Sarah Cannon Research Institute phase II trial J Clin Oncol 29 suppl 7 2011 abstr 4659
34. J.A. Reeves, D.R. Spigel, D.B. Daniel, E.K. Friedman, H.A. Burris, and J.D. Hainsworth Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: a Sarah Cannon Research Institute phase II trial J Clin Oncol 29 suppl 7 2011 abstr 4659
35. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 1 2009 61 67
36. M.P. Sablin, S. Negrier, and A. Ravaud Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 1 2009 29 34
37. E. Calvo, B. Escudier, and R.J. Motzer Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study Eur J Cancer 48 3 2012 333 339